1-13 of 13
Katherine T. Marcucci, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Shannon L Maude, MD PhD, George E Hucks, Colleen Callahan, Diane Baniewicz, Christina Fasano, Christine Barker, Susan R. Rheingold, MD, Richard Aplenc, MD, Amanda M. Dinofia, MD, Amanda Li, MD BSc, David T Teachey, MD, David M. Barrett, Jennifer Brogdon, PhD, Regina M Young, PhD, John Scholler, Katherine T Marcucci, PhD, Bruce L Levine, PhD, Noelle Frey, MD, David L Porter, MD, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Stephan A Grupp, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1319.
https://doi.org/10.1182/blood.V130.Suppl_1.1319.1319
Published: 2017
Journal Articles

Clinical Evidence That Deficiency of the Methylcytosine Dioxygenase TET2 Gene Promotes the Clonal Expansion and Therapeutic Efficacy of CD19-Directed T Cells

Joseph A Fraietta, PhD, Christopher L Nobles, PhD, Morgan A Sammons, PhD, Shannon A. Carty, MD, Stefan M Lundh, BS, Tyler Reich, Alexandria P Cogdill, BS, MB, Mercy Gohil, Jennifer J.D. Morrissette, PhD, Irina Kulikovskaya, Farzana Nazimuddin, MS, Minnal Gupta, Yan Wang, PhD, Xiaojun Liu, Regina M Young, PhD, David E Ambrose, Martha S Jordan, PhD, Katherine T Marcucci, PhD, Bruce L Levine, PhD, Yangbing Zhao, PhD MD, Michael Kalos, PhD, David L Porter, MD, Simon F Lacey, PhD BS, Shelley L Berger, PhD BS, Frederic D Bushman, PhD, Carl H June, MD, J. Joseph Melenhorst, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1909.
https://doi.org/10.1182/blood.V130.Suppl_1.1909.1909
Published: 2017
Journal Articles

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Marco Ruella, MD, Shannon L Maude, MD PhD, Boris Engels, PhD, David M. Barrett, Noelle Frey, MD, Katherine T Marcucci, PhD, Olga Shestova, PhD, Nathan Singh, MD, Jessica Perazzelli, PhD, David A Christian, PhD, Dana Haagen, BS, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, David L Porter, MD, Carl H June, MD, Stephan A Grupp, MD PhD, Saar I. Gill, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 807.
https://doi.org/10.1182/blood.V130.Suppl_1.807.807
Published: 2017
Journal Articles

Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL)

Jakub Svoboda, MD, Susan R. Rheingold, MD, Saar I Gill, MD PhD, Stephan A Grupp, MD PhD, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Irina Kulikovskaya, Brandon Loudon, Naseem Kerr, MPH, Katherine T Marcucci, PhD, Kim-Marie Shea, RN, Aliza Schmidt, MS, Lester Lledo, RN,MSN,CNP, Amy Marshall, Anthony R. Mato, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Matthew R. Youngman, BS, Bruce L Levine, PhD, David L Porter, MD, Carl H June, MD, Stephen J. Schuster, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 653.
https://doi.org/10.1182/blood.V130.Suppl_1.653.653
Published: 2017
Journal Articles

Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, "Double Hit" Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Elise A. Chong, MD, Nicole Winchell, Daniel J. Landsburg, MD, David L. Porter, MD, Anthony R. Mato, MD, Honore T Strauser, April M. Schrank-Hacker, Mariusz A Wasik, MD, Simon Francis Lacey, PhD BS, Jan Joseph Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Carl H June, MD
Journal: Blood
Blood (2016) 128 (22): 3026.
https://doi.org/10.1182/blood.V128.22.3026.3026
Published: 2016
Journal Articles

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Nicole Winchell, Daniel J. Landsburg, MD, Anthony R. Mato, MD, Simon F. Lacey, PhD, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD
Journal: Blood
Blood (2016) 128 (22): 1100.
https://doi.org/10.1182/blood.V128.22.1100.1100
Published: 2016
Journal Articles

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Shannon L Maude, MD PhD, David M. Barrett, MD PhD, Susan R. Rheingold, MD, Richard Aplenc, MD PhD, David T Teachey, MD, Colleen Callahan, MSN, Diane Baniewicz, MSN, Claire White, BSN, Mala K. Talekar, MD, Pamela A Shaw, PhD, Jennifer L Brogdon, PhD, Regina M Young, PhD, John Scholler, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Noelle Frey, MD MS, David L Porter, MD, Simon F. Lacey, PhD, J. Joseph Melenhorst, PhD, Carl H June, MD, Stephan A. Grupp, MD PhD
Journal: Blood
Blood (2016) 128 (22): 217.
https://doi.org/10.1182/blood.V128.22.217.217
Published: 2016
Journal Articles

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

Karen Thudium Mueller, PharmD, MS, Abhijit Chakraborty, PhD, Patricia A Wood, MD PhD, Rakesh Awasthi, BPharm, Alfonso Quintas-Cardama, MD, Xia Han, MS, Shannon L Maude, MD PhD, Stephan A. Grupp, MD PhD, David L Porter, MD, Noelle Frey, MD MS, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Jan J. Melenhorst, PhD, Carl H June, MD, Simon F. Lacey, PhD
Journal: Blood
Blood (2016) 128 (22): 220.
https://doi.org/10.1182/blood.V128.22.220.220
Published: 2016
Journal Articles

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Shannon L Maude, MD PhD, David M. Barrett, MD PhD, David E Ambrose, Susan R. Rheingold, MD, Richard Aplenc, MD PhD, David T Teachey, MD, Colleen Callahan, MSN, Christine S Barker, Maya Mudambi, Pamela A Shaw, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, John Scholler, Andreas Loew, PhD, Katherine T. Marcucci, PhD, Jeffrey Finklestein, Irina Kulikovskaya, PhD, Farzana Nazimuddin, Zhaohui Zheng, MS, Bruce L. Levine, PhD, David L Porter, MD, Simon F. Lacey, PhD BS, Jan J. Melenhorst, PhD, Carl H. June, MD, Stephan A. Grupp, MD PhD
Journal: Blood
Blood (2015) 126 (23): 683.
https://doi.org/10.1182/blood.V126.23.683.683
Published: 2015
Journal Articles

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Elise A. Chong, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD MSCE, Simon F. Lacey, PhD BS, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Gaurav D. Shah, MD, Mariusz A. Wasik, MD, Katherine T. Marcucci, PhD, Zhaohui Zheng, MS, Bruce L. Levine, PhD, Carl H. June, MD
Journal: Blood
Blood (2015) 126 (23): 183.
https://doi.org/10.1182/blood.V126.23.183.183
Published: 2015
Journal Articles

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Elise A. Chong, MD, Yolanda Mahnke, PhD, Simon F. Lacey, PhD BSc, J. Joseph Melenhorst, PhD, Anne Chew, PhD, Gaurav Shah, MD, Jens Hasskarl, MD, Manuel Litchman, MD, Mariusz A. Wasik, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD MSCE, Alfred L. Garfall, MD, Noelle V. Frey, MDMS, Katherine T. Marcucci, PhD, Joanne Shea, RN, Holly McConville, RN, BSN, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD
Journal: Blood
Blood (2014) 124 (21): 3087.
https://doi.org/10.1182/blood.V124.21.3087.3087
Published: 2014
Journal Articles

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

David L. Porter, MD, Noelle V. Frey, MDMS, J. Joseph Melenhorst, PhD, Wei-Ting Hwang, PhD, Simon F. Lacey, PhD BSc, Pamela Shaw, PhD, Anne Chew, PhD, Stephan A. Grupp, MD PhD, James Capobianchi, Joan Gilmore, Michael Kalos, PhD, Manuel Litchman, MD, Lester Lledo, RN,MSN,CNP, Alison Wakoff Loren, MDMS, Yolanda Mahnke, PhD, Katherine T. Marcucci, PhD, Holly McConville, RN, Angela Shen, MD, Patricia A. Wood, MD PhD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD
Journal: Blood
Blood (2014) 124 (21): 1982.
https://doi.org/10.1182/blood.V124.21.1982.1982
Published: 2014
Journal Articles

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

David L. Porter, MD, Simon F. Lacey, PhD BSc, Wei-Ting Hwang, PhD, Pamela Shaw, PhD, Noelle V. Frey, MDMS, Anne Chew, PhD, Fang Chen, PhD, Michael Kalos, PhD, Vanessa Gonzalez, PhD, Katherine T. Marcucci, PhD, Shannon L Maude, MD PhD, Jan J Melenhorst, PhD, Manuel Litchman, MD, David T. Teachey, MD, Angela Shen, MD, Alfonso Quintas-Cardamas, MD, Patricia A. Wood, MD PhD, Bruce L. Levine, PhD, Carl H. June, MD, Stephan A. Grupp, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1983.
https://doi.org/10.1182/blood.V124.21.1983.1983
Published: 2014